Nevertheless, when exploring the effect of sclerostin on CVEs, all-cause/cardiovascular mortality and VCs in patients with CKD, contradictory data exist mainly due to heterogeneity of participants and observation periods. This evidence concerns the gene SOST and chronic kidney disease.